J

Jazz Pharmaceuticals

Biopharmaceuticals focused on neuroscience and oncology

Executive Director, Assistant General Counsel - Intellectual Property

Full-TimeUpdated on 10/23/2026
$288k - $432k
Expert
Bachelor's, Master's
Pennsylvania, USA+1 moreMore locations: California, USA
Remote
LegalIntellectual Property (IP)

About the job

Requirements
  • Experience managing intellectual property practitioners and staff.
  • Significant experience in intellectual property due diligence and licensing and collaboration agreements.
  • Fully qualified U.S. Patent Attorney with 12 or more years of relevant intellectual property experience in the biopharmaceutical industry, including significant in-house or combined in-house and law firm experience.
  • An undergraduate degree in biological science, biochemistry, chemistry, or another field relevant to pharmaceuticals, life sciences, or biotechnology.
  • Ability to facilitate and contribute to collaborative decision-making and work effectively on cross-functional teams to achieve business objectives.
  • Ability to work in a dynamic, fast-paced team environment, act flexibly and responsively, and work independently as well as collaboratively across the business.
  • Excellent oral and written communication skills, including experience presenting and concisely communicating complex information to all organizational levels.
  • Ability to approach intellectual property creation and protection strategically by anticipating business challenges, competitive and legal risks and opportunities, and offering creative solutions.
  • Ability to manage outside counsel and other external resources to ensure quality work product, value, and efficiency.
  • Strong prioritization skills and ability to effectively manage a diverse workload.
  • Commitment to diversity, equity, inclusion, and community.
Responsibilities
  • Advise senior leadership, Research and Development, Commercial, and Corporate Development teams on complex intellectual property matters to advance corporate objectives.
  • Directly and indirectly supervise intellectual property team members supporting programs and projects across the company portfolio.
  • Develop and execute global patent strategies that support business objectives, strengthen competitive positioning and exclusivity, and maximize the value of internally developed, acquired, or licensed assets.
  • Conduct intellectual property due diligence for potential acquisitions, in-licensing opportunities, collaborations, and strategic partnerships, including freedom-to-operate evaluations, portfolio strength analyses, exclusivity assessments, and identification of material intellectual property risks and value drivers.
  • Identify opportunities to strengthen the intellectual property portfolio through engagement with project teams and collaboration partners, using knowledge of patent law and the portfolio's competitive landscape.
  • Provide freedom-to-operate, infringement, and validity analyses, risk evaluations, and mitigation strategies for programs, technologies, and tools.
  • Provide strategic input into transaction documents, including licensing, collaboration, and acquisition agreements; due diligence reports; representations and warranties; intellectual property covenants; and integration-related provisions.
  • Manage outside counsel supporting patent prosecution, intellectual property due diligence, litigation, opinions, and other strategic matters to ensure high-quality, efficient, and commercially focused outcomes.
  • Counsel and train internal clients, including Legal Department members and senior management, on intellectual property risks and opportunities involving patentability, freedom to operate, infringement, validity, and regulatory exclusivity.
  • Review publications, presentations, press releases, and other materials for clearance.
  • Advise on or lead contentious and adversarial matters involving company assets, including patent litigation, inter partes reviews, post-grant reviews, European oppositions, and related proceedings.
  • Lead and participate in intellectual property team and Legal Department initiatives, identifying opportunities to improve departmental effectiveness and operations.
Desired Qualifications
  • Experience in adversarial and administrative proceedings is a plus.
  • An advanced degree is preferred.

About the company

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $1.21 billion; Jazz raised full-year guidance to $4.68 billion.
  • Actio's ABS-1230 adds first-in-class KCNT1 epilepsy upside after the September 15, 2026 close.
  • Oncology revenue exceeded $1 billion in 2025, driven by Zepzelca and Ziihera.

What critics are saying

  • Xywav faces Lupin, Teva, and Tris patent fights; generic entry threatens 2027 cash flow.
  • Xywav and EPIDIOLEX still dominate value; one patent loss or safety issue would crush earnings.
  • Jazz paid $820 million for Actio before registrational proof; ABS-1230 can still fail.

What makes Jazz Pharmaceuticals unique

  • Ziihera launched August 2026, targeting $3B-$5B across HER2-positive tumors.
  • EPIDIOLEX holds exclusivity into the late 2030s and now funds four new trials.
  • Xywav's low-sodium oxybate formulation keeps narcolepsy patients despite generic Xyrem pressure.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • Paid Vacation

Growth & Insights and Company News

6 month growth

0%

1 year growth

1%

2 year growth

0%
Yahoo Finance
Oct 16th, 2026
Jazz wins FDA approval for Ziihera as commercial chief Pearce plans to retire; 2026 guidance $4.6B+

Jazz Pharmaceuticals has won US Food and Drug Administration (FDA) approval for its cancer drug Ziihera. The approval raised the drug's projected peak sales range. Separately, chief commercial officer Samantha Pearce plans to retire by June 30, 2027, or when a successor is appointed. Jazz has started an internal and external search. In its second-quarter 2026 update, Jazz reported revenue of $1,208.3 million and raised full-year 2026 guidance to $4.60–4.75 billion. The share price still fell 7.6% after earnings. Simply Wall St's narrative projects revenue of $5.7 billion and earnings of $1.7 billion by 2029, implying a fair value of $294.27 a share.

Yahoo Finance
Sep 20th, 2026
Jazz Pharma raises zanidatamab peak sales target to $3B-$5B as oncology revenue hits $1B

Jazz Pharmaceuticals reported its oncology revenue surpassed $1 billion in 2025, marking a 32% year-over-year increase. The growth follows three recent product launches, including zanidatamab, Modeyso and Zepzelca's FORTE regimen. The company raised zanidatamab's estimated peak-sales opportunity to $3 billion-$5 billion. Jazz aims to increase HER2-directed treatment adoption in gastroesophageal cancer, where only 60% of eligible HER2-positive patients currently receive such therapy. Jazz estimates the US incidence of HER2-positive gastroesophageal adenocarcinoma at approximately 8,000 patients, with a labelled population of 3,000 to 4,000 patients. The company is also developing zanidatamab for biliary tract cancer, colorectal cancer, non-small cell lung cancer and breast cancer. Jazz maintains commercial investment whilst preserving financial flexibility for acquisitions across oncology, epilepsy and sleep disorders.

Yahoo Finance
Sep 11th, 2026
Jazz Pharmaceuticals stock climbs 29.7% but analysts warn of declining margins and weak returns

Jazz Pharmaceuticals' stock has risen 29.7% over the past six months, outpacing the S&P 500 by 17 percentage points to reach $240.49 per share. However, analysts point to concerning trends in the company's fundamentals. The company's adjusted operating margin has declined by 2.6 percentage points over five years, despite revenue growth that should have improved economies of scale. Its trailing 12-month adjusted operating margin stood at 41.7%. Additionally, Jazz Pharmaceuticals' five-year average return on invested capital was just 2.7%, below the typical cost of capital for healthcare companies. This suggests mediocre efficiency in deploying capital for growth. The stock currently trades at 9.6× forward price-to-earnings ratio. Analysts consider this valuation reasonable but believe the company's weakening fundamentals present downside risk.

StockTitan
Aug 27th, 2026
Jazz Pharmaceuticals prices upsized $1.1B exchangeable notes offering with $225M share repurchase

Jazz Pharmaceuticals has priced an upsized $1.1 billion private offering of 1.875% exchangeable senior notes due 2032, up from the previously announced $1.0 billion. The offering, conducted through its wholly-owned subsidiary Jazz Investments I Limited, is expected to close on 31 August 2026. The notes will mature on 15 September 2032 and are exchangeable at an initial rate of 2.8150 ordinary shares per $1,000 principal amount, equivalent to an exchange price of approximately $355.24 per share. This represents a 42.5% premium above the last reported sale price on 26 August 2026. The company will use net proceeds of approximately $1,079 million for general corporate purposes. Concurrently, Jazz Pharmaceuticals agreed to repurchase approximately $225 million of its ordinary shares from note purchasers at $249.29 per share, using existing cash on hand.

Yahoo Finance
Aug 26th, 2026
Jazz Pharmaceuticals launches Ziihera for HER2-positive cancer with $3B–$5B peak sales outlook

Jazz Pharmaceuticals has launched Ziihera in the US following FDA approval for first-line treatment of HER2-positive, unresectable or metastatic gastroesophageal adenocarcinoma. The drug can be used with tislelizumab and chemotherapy, or with chemotherapy alone for certain patients. In the Phase III HERIZON-GEA-01 trial, Ziihera-based regimens reduced the risk of disease progression or death by 35%. The triplet regimen extended median overall survival to 26.4 months, a 28% reduction in death risk versus trastuzumab. Jazz estimates the US addressable market at 3,000–4,000 patients annually and raised Ziihera's peak sales outlook to $3 billion–$5 billion. The company plans to leverage existing commercial infrastructure whilst pursuing additional cancer indications and international regulatory filings.